Tomopenem
Alternative Names: CS-023; R 115685; R 1558; RO 4908463Latest Information Update: 13 Aug 2009
At a glance
- Originator Daiichi Sankyo Company
- Class Antibacterials; Carbapenems; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Community-acquired pneumonia; Gram-negative infections; Gram-positive infections; Skin and soft tissue infections
Most Recent Events
- 13 May 2008 Discontinued - Phase-II for Gram-negative infections in USA (IV)
- 13 May 2008 Discontinued - Phase-II for Gram-positive infections in European Union (IV)
- 13 May 2008 Discontinued - Phase-II for Bacterial infections in European Union (IV)